Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Avesani, Barbara
Giontella, Elena
Caldart, Alberto
De Noni, Alessandro
Muzzarelli, Alice
Borghesani, Giulia
Insolda, Jessica
Biondani, Pamela
Parolin, Veronica
Pellini, Francesca
Scarpa, Aldo
Nottegar, Alessia
Lawlor, Rita T.
Mafficini, Andrea
Paris, Ida
Minucci, Angelo
Pasciuto, Tina
Fabi, Alessandra
Fiorio, Elena
Milella, Michele
机构：
[1] Azienda Osped Univ Integrata Verona, Med Oncol, Verona, Italy
[2] Azienda Osped Univ Integrata Verona, Verona, Italy
[3] Azienda Osped Univ Integrata Verona, Sect Breast Surg, Verona, Italy
[4] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy
[5] Hosp Trust Verona, Verona, Italy
[6] Univ Verona, Sect Pathol, Verona, Italy
[7] ARC NET, Verona, Italy
[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[9] Univ Cattolica Sacro Cuore, Dept Unit Mol & Genom Diagnost, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[10] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy
[11] IRCCS, Precis Med Senol, Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[12] Univ Verona Hosp Trust, Dept Oncol, Verona, Italy
[13] Univ Verona, Sch Med, Sect Oncol, Verona, Italy
[14] Verona Univ Hosp Trust, Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13079
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Frontline Fulvestrant, Palbociclib Combo Is Effective for Endocrine-Sensitive, HR+/HER2-Metastatic Breast Cancer
    不详
    ONCOLOGY-NEW YORK, 2020, 34 (11): : 486 - 486
  • [42] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer
    Cuyun Carter, Gebra
    Sheffield, Kristin M.
    Gossai, Anala
    Huang, Yu-Jing
    Zhu, Yajun Emily
    Bowman, Lee
    Nash Smyth, Emily
    Mathur, Raina
    Cohen, Aaron B.
    Rasmussen, Erik
    Balakrishna, Shreya
    Morato Guimaraes, Claudia
    Rybowski, Sarah
    Seidman, Andrew D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (07) : 1179 - 1187
  • [43] Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience
    Caldart, A.
    Fiorio, E.
    Zanelli, S.
    Biondani, P.
    Parolin, V.
    Pellini, F.
    Montemezzi, S.
    Nottegar, A.
    Calio, A.
    Zampiva, I.
    Merler, S.
    Mongillo, M.
    Avesani, B.
    Borghesani, G.
    Giontella, E.
    Scarpa, A.
    Milella, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S38 - S39
  • [44] Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
    Merlin, J. L.
    Husson, M.
    Sahki, N.
    Gilson, P.
    Leroux, A.
    Massard, V.
    Harle, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1190 - S1190
  • [45] Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)
    Merlin, Jean-Louis
    Husson, Marie
    Sahki, Nassim
    Gilson, Pauline
    Massard, Vincent
    Harle, Alexandre
    Leroux, Agnes
    BIOMEDICINES, 2023, 11 (12)
  • [46] Real-world clinical outcomes in patients (pts) with HR+/HER2-metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US)
    Tolaney, Sara M.
    Punie, Kevin
    Kurian, Allison W.
    Ntalla, Ioanna
    Verret, Wendy
    Sadetsky, Natalia
    Sjekloca, Nikoleta
    Stokes, Michael
    Jhaveri, Komal L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
    Martinez-Janez, Noelia
    Ezquerra, Meritxell Bellet
    Henao, Fernando
    Manso, Luis
    Anton, Antonio
    Zamora, Pilar
    Murillo, Serafin Morales
    Tolosa, Pablo
    Andres, Raquel
    Calvo, Lourdes
    Galve, Elena
    Lopez, Rafael
    de la Pena, Francisco Ayala
    Lopez-Tarruella, Sara
    Boronat, Laia
    Martos, Tamara
    Chacon, J. Ignacio
    Alvarez, Isabel
    de la Haba-Rodriguez, Juan
    Anton, Fernando Moreno
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2-metastatic breast cancer
    Robert, Nicholas
    Chen, Connie
    Kim, Sindy
    Zhang, Zhe
    Aguilar, Kathleen M.
    Wang, Yunfei
    Li, Benjamin
    Gaffney, Michael
    Huang, Xin
    Mcroy, Lynn
    FUTURE ONCOLOGY, 2024, 20 (12) : 761 - 780
  • [49] Ribociclib Improves Overall Survival in HR+/HER2-Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
    Jacobson, Anne
    ONCOLOGIST, 2022, 27 (SUPPL 1): : S11 - S12
  • [50] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
12345